Abstract: Real-time decision-making for a vehicle using belief state determination is described. Operational environment data is received while the vehicle is traversing a vehicle transportation network, where the data includes data associated with an external object. An operational environment monitor establishes an observation that relates the object to a distinct vehicle operation scenario. A belief state model of the monitor computes a belief state for the observation directly from the operational environment data. The monitor provides the computed belief state to a decision component implementing a policy that maps a respective belief state for the object within the distinct vehicle operation scenario to a respective candidate vehicle control action. A candidate vehicle control action is received from the policy of the decision component, and a vehicle control action is selected for traversing the vehicle transportation from any available candidate vehicle control actions.

Abstract: The invention relates to isolated nucleic acids and rAAV-based compositions, methods and kits useful for treating genetic diseases (e.g., alpha-1 antitrypsin deficiency).

Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having nuclease grafted to one or more capsid proteins. In some aspects, the disclosure relates to isolated AA V capsid proteins having terminally grafted nucleases and isolated nucleic acids encoding the same. Recent approaches to delivering nucleases to cells for gene editing have focused on delivering of expression vectors engineered to express the nucleases in target cells. However, these approaches have proved to be problematic in many instances due to genotoxicity resulting from to prolonged expression of gene editing system in vivo. To prevent such off-target genotoxicity due to prolonged presence of a gene editing system, several studies explored delivery of mRNA or protein instead of delivering the gene coding for the nucleases in cell culture.

Abstract: A unique point absorber type wave energy conversion device is disclosed that includes a Power Take Off (PTO) which uses a torsion spring to return a vertical shaft to its original position after being rotated by a rope or cord that pulls a reel via a guide system. This spring return allows the PTO and housing to stay stationary under the wave energy while a buoy at the surface provides an oscillating linear movement. The oscillating rotary motion caused by the interaction of the buoy and spring is converted into a one directional motion via a one-way clutch and is transmitted to generators using a gearbox that increases rotational speed.

Abstract: Methods and compositions for treating cancer, e.g., prostate cancer, using a combination of P-Rex1 or Rac1 inhibitors and VEGF/VEGFR-targeted therapy.

Abstract: A temozolomide compound according to formula (I) is described, wherein R1, L1, and X are defined herein. The temozolomide compound can be used to prepare polymers comprising temozolomide. Additionally, the polymers comprising temozolomide can be particularly useful in the treatment of certain diseases.

Abstract: Systems, devices, and methods of the present application relate to the diagnostic measurement of condition for pressure ulcers. Preferred embodiments utilize pressure measurements at body locations to determine a diagnostic pressure ulcer value. A pressure sensor device generates patient pressure data that is processed by a data processor which utilizes a diagnostic function to determine the diagnostic value that indicates whether corrective action is needed to prevent pressure ulcer formation. One or more sensor devices can be attached to a patient to measure to transmit data for further processing.

Abstract: Among other concepts, this disclosure describes a thermal/optical/electronic authentication system (covert or non-covert) for device/system implementations. The authentication system may be based on different design parameters such as i) materials composition, ii) thickness of material, iii) geometry of material, iv) external effects including use of an external DC bias and curing, etc. The authentication testbeds can be configured to include one or more inks. Using such methods as discussed herein, the authentication can be broadened to include near-IR (700-900 nm), short wave IR (1-2.6 mm), and UVA (300-400 nm) or any spectrum. Printed resistors are very difficult to duplicate without Ag-BST13 ink. If necessary, a printed resistor network on a respective substrate can be hidden using a layer of non-sintered Ag-BST13 (non-conductive).

Abstract: An autonomous vehicle traverses a vehicle transportation network using a multi-objective policy based on a model for specific scenarios. The multi-objective policy includes a topographical map that shows a relationship between at least two objectives. The autonomous vehicle receives a candidate vehicle control action associated with each of the at least two objectives. The autonomous vehicle selects a vehicle control action based on a buffer value that is associated with the at least two objectives. The autonomous vehicle traverses a portion of the vehicle transportation network in accordance with the selected vehicle control action.

Abstract: Provided herein are branched oligonucleotides exhibiting efficient and specific tissue distribution, cellular uptake, minimum immune response and off-target effects, without formulation.

Abstract: Absolute blood volume in dialysis patients is a useful patient attribute to know for dialysis treatment, diagnosis, adjustments, etc. In some cases, it is difficult or impossible to directly determine absolute blood volume. Estimating absolute blood volume may be used to overcome the inability to directly determine the absolute blood volume. Estimating absolute blood volume may include obtaining a series of measurements of hemoconcentration of a patient over a time period, and estimating parameters for a physiological model based on the series of measurements. The absolute blood volume of the patient may be determined using the physiological model.

Abstract: In some aspects, the disclosure relates to methods for improving titer and yield of viral vector production. In some embodiments, the methods comprise transient silencing of transgene expression during packaging of a viral vector.

Abstract: Methods of preparing protein films in the presence of organofluorine compounds are provided that can produce protein films that retain the solution phase characteristics of the proteins. The protein films can be coatings for medical devices.

Abstract: In some aspects, the disclosure relates to compositions and methods for production of recombinant adeno-associated virus (rAAV) particles. The disclosure is based, in part, on isolated nucleic acids and systems that include only two vectors and are suitable for production of multiple different single gene viral vectors in a multiple small-scale campaign mode (e.g., 1013 to 1016 viral particles.

Abstract: The disclosure, in some aspects, relates to methods and compositions for recombinant adeno-associated virus (rAAV)-mediated delivery of genome editing molecules to a pre-implantation embryo.

Abstract: Techniques for generating a stylized drawing of three-dimensional (3D) shapes using neural networks are disclosed. A processing device generates a set of vector curve paths from a viewpoint of a 3D shape; extracts, using a first neural network of a plurality of neural networks of a machine learning model, surface geometry features of the 3D shape based on geometric properties of surface points of the 3D shape; determines, using a second neural network of the plurality of neural networks of the machine learning model, a set of at least one predicted stroke attribute based on the surface geometry features and a predetermined drawing style; generates, based on the at least one predicted stroke attribute, a set of vector stroke paths corresponding to the set of vector curve paths; and outputs a two-dimensional (2D) stylized stroke drawing of the 3D shape based at least on the set of vector stroke paths.

Abstract: Traversing, by an autonomous vehicle, a vehicle transportation network, may include identifying a distinct vehicle operational scenario, wherein traversing the vehicle transportation network includes traversing a portion of the vehicle transportation network that includes the distinct vehicle operational scenario, communicating shared scenario-specific operational control management data associated with the distinct vehicle operational scenario with an external shared scenario-specific operational control management system, operating a scenario-specific operational control evaluation module instance including an instance of a scenario-specific operational control evaluation model of the distinct vehicle operational scenario, and wherein operating the scenario-specific operational control evaluation module instance includes identifying a policy for the scenario-specific operational control evaluation model, receiving a candidate vehicle control action from the policy for the scenario-specific operational contr

Abstract: Methods of treating subjects having disorders associated with mutations in the FXN gene and/or having reduced expression of frataxin protein, e.g., Friedreich ataxia (FA). Generally, the methods include administering a therapeutically effective amount of an agent that increases expression of frataxin protein as described herein, e.g., an inhibitor of a FXN Repressing Factor (FXN-RF).

Abstract: The disclosure provides novel methods and compositions for gene editing. In particular, the disclosure relates to compositions and methods of making nucleic acid donor templates for highly efficient and precise gene editing.

Abstract: Disclosed herein are methods and compositions for treating neutrophil-mediated inflammation by targeting, in any combination, the pro-inflammatory MRP2/HXA3 pathway and/or the anti-inflammatory P-gp/endocannabinoid pathway and/or the anti-inflammatory MRP 1/L-AMEND pathway, comprising administering to the subject a therapeutically effective amount of (a) one or more first compound that inhibits the activity and/or level of one or more of multidrug resistance protein 2 (MRP2) and hepoxilin A3 (HXA3) synthase, and/or (b) one or more second compound that increases the level and/or activity of one or more N-acylethanolamines (NAEs), and/or (c) one or more third compound that increases the level and/or activity of multidrug resistance protein 1 (MRP1), wherein the therapeutic amount of the first, second, and third compounds reduces migration of neutrophils into the target tissue.